Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 19

1.

Peginterferon alfa-2a/ribavirin for 48 or 72 weeks in hepatitis C genotypes 1 and 4 patients with slow virologic response.

Ferenci P, Laferl H, Scherzer TM, Maieron A, Hofer H, Stauber R, Gschwantler M, Brunner H, Wenisch C, Bischof M, Strasser M, Datz C, Vogel W, Löschenberger K, Steindl-Munda P; Austrian Hepatitis Study Group.

Gastroenterology. 2010 Feb;138(2):503-12, 512.e1. doi: 10.1053/j.gastro.2009.10.058. Epub 2009 Nov 10.

PMID:
19909752
[PubMed - indexed for MEDLINE]
2.

Very early viral kinetics on interferon treatment in chronic hepatitis C virus genotype 4 infection.

Jessner W, Gschwantler M, Formann E, Gurguta C, Watkins-Riedel T, Wrba F, Ferenci P.

Antivir Ther. 2008;13(4):581-9.

PMID:
18672537
[PubMed - indexed for MEDLINE]
3.

Peginterferon alfa-2a and ribavirin for 24 weeks in hepatitis C type 1 and 4 patients with rapid virological response.

Ferenci P, Laferl H, Scherzer TM, Gschwantler M, Maieron A, Brunner H, Stauber R, Bischof M, Bauer B, Datz C, Löschenberger K, Formann E, Staufer K, Steindl-Munda P; Austrian Hepatitis Study Group.

Gastroenterology. 2008 Aug;135(2):451-8. doi: 10.1053/j.gastro.2008.04.015. Epub 2008 May 27.

PMID:
18503773
[PubMed - indexed for MEDLINE]
4.

A randomized, prospective trial of ribavirin 400 mg/day versus 800 mg/day in combination with peginterferon alfa-2a in hepatitis C virus genotypes 2 and 3.

Ferenci P, Brunner H, Laferl H, Scherzer TM, Maieron A, Strasser M, Fischer G, Hofer H, Bischof M, Stauber R, Gschwantler M, Steindl-Munda P, Staufer K, Löschenberger K; Austrian Hepatitis Study Group.

Hepatology. 2008 Jun;47(6):1816-23. doi: 10.1002/hep.22262.

PMID:
18454510
[PubMed - indexed for MEDLINE]
5.

Comparison of the Bayer VERSANT HCV RNA 3.0 and the Roche COBAS Amplicor HCV Monitor, Version 2.0, assays in HCV genotype 4 infection.

Jessner W, Watkins-Riedel T, Müller C, Formann E, Gschwantler M, Ferenci P.

J Viral Hepat. 2007 Nov;14(11):775-81.

PMID:
17927613
[PubMed - indexed for MEDLINE]
6.

A mimic of sarcoidosis.

Dzirlo L, Hubner M, Müller C, Blaha B, Formann E, Dellinger C, Petzelbauer P, Müllauer L, Huber K, Kneussl M, Gschwantler M.

Lancet. 2007 May 26;369(9575):1832. No abstract available.

PMID:
17531892
[PubMed - indexed for MEDLINE]
7.

Erythropoietin treatment is associated with more severe thrombocytopenia in patients with chronic hepatitis C undergoing antiviral therapy.

Homoncik M, Sieghart W, Formann E, Schmid M, Ferenci P, Gangl A, Jilma B, Peck-Radosavljevic M.

Am J Gastroenterol. 2006 Oct;101(10):2275-82.

PMID:
17032193
[PubMed - indexed for MEDLINE]
8.

Antiviral therapy decreases GpIIb/IIIa activation of platelets in patients with chronic hepatitis C.

Sieghart W, Homoncik M, Jilma B, Formann E, Ferenci P, Gangl A, Peck-Radosavljevic M.

Thromb Haemost. 2006 Feb;95(2):260-6.

PMID:
16493487
[PubMed - indexed for MEDLINE]
9.

Prospective study of viral clearance and CD4(+) T-cell response in acute hepatitis C primary infection and reinfection.

Aberle JH, Formann E, Steindl-Munda P, Weseslindtner L, Gurguta C, Perstinger G, Grilnberger E, Laferl H, Dienes HP, Popow-Kraupp T, Ferenci P, Holzmann H.

J Clin Virol. 2006 May;36(1):24-31. Epub 2006 Feb 17.

PMID:
16483838
[PubMed - indexed for MEDLINE]
10.

Long-term follow-up of chronic hepatitis C patients with sustained virological response to various forms of interferon-based anti-viral therapy.

Formann E, Steindl-Munda P, Hofer H, Jessner W, Bergholz U, Gurguta C, Ferenci P.

Aliment Pharmacol Ther. 2006 Feb 15;23(4):507-11.

PMID:
16441471
[PubMed - indexed for MEDLINE]
Free Article
11.

Tongue and skin hyperpigmentation during PEG-interferon-alpha/ribavirin therapy in dark-skinned non-Caucasian patients with chronic hepatitis C.

Gurguta C, Kauer C, Bergholz U, Formann E, Steindl-Munda P, Ferenci P.

Am J Gastroenterol. 2006 Jan;101(1):197-8.

PMID:
16405555
[PubMed - indexed for MEDLINE]
12.

Randomized, double-blind, placebo-controlled study of peginterferon alfa-2a (40KD) plus ribavirin with or without amantadine in treatment-naïve patients with chronic hepatitis C genotype 1 infection.

Ferenci P, Formann E, Laferl H, Gschwantler M, Hackl F, Brunner H, Hubmann R, Datz C, Stauber R, Steindl-Munda P, Kessler HH, Klingler A, Gangl A; Austrian Hepatitis Study Group.

J Hepatol. 2006 Feb;44(2):275-82. Epub 2005 Nov 7.

PMID:
16338019
[PubMed - indexed for MEDLINE]
13.

Relative impact of fatigue and subclinical cognitive brain dysfunction on health-related quality of life in chronic hepatitis C infection.

Kramer L, Hofer H, Bauer E, Funk G, Formann E, Steindl-Munda P, Ferenci P.

AIDS. 2005 Oct;19 Suppl 3:S85-92.

PMID:
16251834
[PubMed - indexed for MEDLINE]
14.

Successful treatment of chronic hepatitis D with a short course of peginterferon alfa-2a.

Ferenci P, Formann E, Romeo R.

Am J Gastroenterol. 2005 Jul;100(7):1626-7. No abstract available.

PMID:
15985000
[PubMed - indexed for MEDLINE]
15.

Short- and long-term effects of therapy with interferon-alpha and pegylated interferon-alpha/ribavirin on platelet plug formation and von Willebrand factor release in patients with chronic hepatitis C.

Homoncik M, Ferlitsch A, Ferenci P, Formann E, Jilma B, Gangl A, Panzer S, Peck-Radosavljevic M.

Aliment Pharmacol Ther. 2005 Jan 1;21(1):49-55.

PMID:
15644045
[PubMed - indexed for MEDLINE]
Free Article
16.

Sudden hearing loss in patients with chronic hepatitis C treated with pegylated interferon/ribavirin.

Formann E, Stauber R, Denk DM, Jessner W, Zollner G, Munda-Steindl P, Gangl A, Ferenci P.

Am J Gastroenterol. 2004 May;99(5):873-7.

PMID:
15128353
[PubMed - indexed for MEDLINE]
17.

Twice-weekly administration of peginterferon-alpha-2b improves viral kinetics in patients with chronic hepatitis C genotype 1.

Formann E, Jessner W, Bennett L, Ferenci P.

J Viral Hepat. 2003 Jul;10(4):271-6.

PMID:
12823593
[PubMed - indexed for MEDLINE]
18.

Hepatitis C viral dynamics: basic concept and clinical significance.

Jessner W, Watkins-Riedel T, Formann E, Steindl-Munda P, Ferenci P.

J Clin Virol. 2002 Dec;25 Suppl 3:S31-9. Review.

PMID:
12467775
[PubMed - indexed for MEDLINE]
19.

The impact of positive peritoneal washings and serosal and adnexal involvement on survival in patients with stage IIIA uterine cancer.

Preyer O, Obermair A, Formann E, Schmid W, Perrin LC, Ward BG, Crandon AJ, Nicklin JL.

Gynecol Oncol. 2002 Sep;86(3):269-73.

PMID:
12217747
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk